GDF-9 plays a prominent role in female fertility. It is an oocyte-secreted factor, and GDF-9 mutations have been linked to ovarian dysfunction. Approximately 10% of all women under the age of 40 experience increased follicular expenditure and diminished ovarian reserve (DOR).

DOR is an ovarian disorder in which women experience smaller numbers and poorer quality of oocytes. This disorder leads elevated chance of miscarriage in women, infertility, and makes them poor candidates for IVJ and embryo transfer. Recent studies reveal that there are likely genetic factors in DOR. Genetic variations, such as fragile mental retardation 1 (FMR-1), steroidogenic factor 1 (SF-1), and growth differentiation factor 9 (GDF-9) increase the rapid decline of ovarian dysfunction.

GDF-9 is the first-ever identified oocyte-secreted factor belonging to the transforming growth factor -B (TGF-B) superfamily. In mammals, oocytes express GDF-9 within the ovaries, because somatic cells are necessary for folliculogenesis. As with other elements within the TGF-B superfamily, GDF-9 is created as a proprotein made of only one peptide.

Test rodents with GDF-9 deficiencies are always entirely infertile because the many defects GDF-9 deficiencies cause in the ovaries. These deficiencies include degenerated oocytes, blocks in folliculogenesis, altered GC differentiation, and more. However, male rodents with GDF-9 deficiencies are not affected.

It has been discovered that recombinant GDF-9 encourages the transition of pre-antral follicles to antral follicles. Recombinant GDF-9 also promotes oocyte competence. These discoveries support the theory that GDF-9 deficiencies prevent folliculogenesis as well as oogenesis. Premature ovarian failure, diminished ovarian reserve, polycystic ovary syndrome, and dizygotic twinning are some of the most common abnormal reproductive health issues women with the GDF-9 deficiencies encounter.

One of the primary factors for figuring out a woman’s ovarian lifespan is the assessment of primordial follicles at the time of birth. Also, assessing the rate of loss from this limited pool in a woman’s mid-adult life. A healthy level and quality of the GDF-9 factor is needed for woman to maintain healthy and normal ovarian function. GDF-9 doesn’t just impact the process of folliculogenesis, it also controls hormone secretion, such as inhibin-B

At Ansh Labs, we provide quality tools for biomedical research. We provide life science researchers, physician researchers, hospitals, commercial labs, and many others with products that help conduct quality and reliable research for the following medical topics:

  • Menopause
    Premature Ovarian Failure (POF)
    Polycystic Ovary Syndrome
    Cancers of the Reproductive System
    Male Infertility
    Assisted Reproductive Technology
    Disorders of Sex Development
    Species-Specific Assays and Crossreactivity

Here are some of our product offerings:

  • Immunoassays
    Reproductive Function
    Growth Factors
    Neuronal Disorders
    Cardiovascular Disease
    Animal Specific Assays
    Research Reagents
    Monoclonal Antibodies

As the applications of GDF-9 continue to develop, you can count on Ansh Labs to be on the cutting-edge of technology. Contact us today to discuss your needs. We always look forward to meeting new friends and collaborators.


Ansh Labs LLC

445 Medical Center Blvd

Webster TX 77598 US

View Larger Map